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ㅋ
The irritable bowel syndrome (IBS) is a complex disorder in which psychosocial, cultural and biological factors, interact. Recent 
knowledge in the pathophysiology of IBS, seem to combine issues such as a low grade inflammation or immune activation 
and dysbiosis that can trigger or exacerbate IBS. On the other hand, stress mediated through the hypothalamic-pitui-
tary-adrenal axis can produce motility abnormalities that can modify the microbiota as well, with the subsequent immune acti-
vation in the mucosa and stimulation of nerve terminals, generating symptoms of IBS. Also, we speculate that, stress, dysbiosis 
or an underlying genetic predisposition, may increase the epithelial permeability leading to a contact between pathogens-asso-
ciated molecular patterns and toll-like receptors in the deeper layers of the gut, developing a host immunity response and IBS 
generation. We believe that the role of toll-like receptors in IBS and elucidating the communication processes between the im-
mune and the nervous system, warrant future research.
(J Neurogastroenterol Motil 2010;16:363-373)
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Tel: +52-55-5623-2673, Fax: +52-55-5623-2669, E-mail: maxjulio@prodigy.net.mx
Financial support: This study was supported in part by grant PAPIIT, IN-210010 of DGAPA, Universidad Autónoma de México (UNAM). 
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Introduction
Traditionally, irritable bowel syndrome (IBS) has been con-
sidered a functional gastrointestinal disorder (FGID), charac-
terized by pain or discomfort associated with changes in bowel 
habit, such as diarrhea, constipation or alternating/mixture.
1 As 
with other FGIDs, in IBS there is no evidence of organic, bio-
chemical or structural abnormalities; however, recent data are 
shaping new concepts. Currently, IBS is diagnosed based on clin-
ical symptoms by the Rome criteria, in the absence of alarm signs; 
but patients usually undergo exhaustive diagnostic evaluations 
looking for organic gastrointestinal pathologies before the diag-
nosis is accepted by both patients and physicians.
2 Despite this, 
IBS is the most common FGID and may affect up to 20% of the 
adult population in industrialized and non industrialized coun-
tries. For example, in non industrialized countries, a 16% preva-
lence of IBS has been reported in the community, and up to 35% 
among volunteers.
3-5 Furthermore, it is the first reason for con-
sultation to gastroenterologists.
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In recent years, new concepts have changed the main interest 
in IBS, energizing a growing group of gastroenterologists and 
scientists around the world. On the one hand, data from several 
groups have begun to blur the division between functional and 
organic disorders.
6 For example, the recognition of inflammation 
in IBS, albeit its low grade,
7 the participation of this in-
flammatory response on gut motility and sensitivity
8 and finally 
the fact that IBS could represent an abnormal mucosal response 
to an altered intestinal microbiota, echoing current theories on in-
flammatory bowel disease (IBD),
9 could answer the long time 
considered convergence between IBD, celiac disease and IBS.
7 
Additionally, there is evidence implicating gastrointestinal in-
fections in the pathogenesis of IBS, the so called post-infectious 
IBS (PI-IBS).
10 With this information, a rapidly growing body 
of evidence has supported a low grade inflammation
11-13 and an 
altered fecal microbiota condition related to the pathogenesis of 
IBS.
14,15 On the other hand, some antibiotics and probiotics have 
proven to reduce symptoms, leading to a new understanding of 
IBS. 
Issues of Interest
  in the Pathophysiology of IBS
1. Genetic factors
During the last decade, studies on familial aggregation
16 and 
on twins
17 have supported the involvement of hereditary factors 
in the pathogenesis of IBS. However, the lack of consistent find-
ings that support a specific genetic mechanism in IBS based on 
symptom phenotypes, has lead to a different approach: the exami-
nation candidate genes associations with FGIDs and with the un-
derlying abnormalities in gastrointestinal and colonic physio-
logy.
18 Examples of this approach include the association of IBS 
with IL-10, serotonin transporter, alpha-2 adrenergic receptors 
and G protein functions. Gonsalkorale et al
19 and van der Veek et 
al
20 reported an association of IL-10 low producer polymorphism 
with the presence of IBS in different populations.
21 The above 
findings have suggested a genetic predisposition for a reduced 
anti-inflammatory response, mediated by a lower production of 
this regulatory cytokine. Additionally, this pro-inflammatory 
condition could be synergistically stimulated, if patients have a 
higher production of tumor necrosis factor-alpha (TNF-α), as 
has been related by high producer polymorphisms in patients 
compared to healthy controls.
20 
Recently, as a consequence of a gastroenteritis outbreak fol-
low-up, Villani et al
22 evaluated the genetic risk factors in patients 
with PI-IBS, reporting statistically significant relationships with 
several genes. The most striking features were the relationships 
between the immunity related toll-like receptor 9 (TLR9), IL-6 
and adhesion E-cadherin 1 polymorphism genes, as risk factors. 
2. Stress
Since the stress concept was borrowed from physics, Hans 
Selye
23 identified the gut, along with the endocrine and immu-
ne systems, as the main targets altered by chemical and physical 
challenges. Recently, there have been several studies relating 
stressful events (psychological stressors) with the development of 
FGIDs such as IBS or symptom exacerbation,
24-26 which intend 
to elucidate the stress related mechanisms that influence the path-
ophysiology of this disorder. 
The release of corticotrophin-releasing factor (CRF) from 
the hypothalamus, in response to diverse physical and psycho-
logical stressors, plays a major role in orchestrating the behav-
ioral, neuroendocrine and autonomic responses to stress.
27,28 The 
hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic 
nervous system are the 2 core branches of this stress response 
system. Abnormalities in the stress response in the form of 
changes in adrenocorticotrophin hormone, cortisol and catechol-
amine levels, have been reported in IBS.
29 In fact, the importance 
of CRF has led research to develop CRF antagonists as possible 
treatments for IBS.
30
Additionally, alterations in the HPA axis have received much 
attention due to its possible implication in a non-standard im-
mune activation in the gut wall,
31 and in symptom exacerbation in 
different IBS subgroups.
32 This non-standard immune activation 
is represented by an abnormal mucosal response to an altered mi-
crobiota including an increase infiltration of mononuclear, mast 
and enteroendocrine cells in the colonic mucosa, but without a 
frank histological inflammation by light microscopy and absence 
of clinical and laboratory markers of inflammation.
9
Also, in order to solve the therapeutic needs related to these 
factors, several groups have turned their scope to exploring the 
efficacy of probiotics, mainly due to the potential effects that can 
be developed by gut derived flora, in symptom improvement 
(pain and discomfort) and low grade inflammation in the in-
testinal mucosa, probably through several mechanisms and inter-
actions, including possible modifications of the HPA axis 
balance.
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Table 1. Immunological Abnormalities and Microbiota-Gut Interactions in Irritable Bowel Syndrome
Study Findings Relevance in IBS
Chadwick et al,
11 2002 Increased numbers of intraepithelial CD3+  Low grade inflammation
  and CD25+ lymphocytes 
Increased numbers of neutrophils and mast cells
Gwee et al,
12 2003 Greater IL-1β mRNA expression during acute  Increased production of 
  gastroenteritis, > 3 months after clearing the infection   pro-inflammatory cytokines
Barbara et al,
31 2004 Activated mast cells in proximity of colonic  Correlated with the severity and frequency of 
  nerve endings   abdominal pain/discomfort
O’Mahony et al,
63 2005 Altered IL-10/IL-12 ratio, indicative of Correlated with improvement in the patients 
  a pro-inflammatory state, normalized with B infantis   symptom scores
Kassinen et al,
15 2007 A significantly altered fecal microbiota in IBS The microbial composition varies between IBS 
  subtypes and controls
Liebregts et al,
13 2007 Higher TNF-α, IL-1β, IL-6 at baseline, Pro-inflammatory cytokines differences
  and IL-6 levels after LPS induction   according to bowel habit predominance
IBS-D presented higher levels of cytokines than IBS-C
Cremon et al,
32 2009 Higher percentage of mucosal immune cells in IBS Inflammatory conditions as a continuum: 
  patients compared to controls, but lower than IBD   Healthy-IBS-IBD. 
Greater number of mast cells in women than men with IBS Immune activation is gender dependent
Piche et al,
78 2009 Changes in intestinal barrier integrity due to paracellular Increased permeability in the gut
  permeability and tight-junction protein expression
Öhman et al,
39,52 2009 Increased T and B cell activation and reduced proliferation Increased immunological activity directed
  in IBS patients with gut homing phenotype   towards the bowel
Villani et al,
22 2010 Genetic risk factors related with acute gastroenteritis that Genetic predisposition to abnormalities
  involved immunity and permeability genes    in immunity and permeability
  (TLR9, IL-6 and CDH1)
IBS, irritable bowel syndrome; LPS, lipopolysaccharide; IBS-D, diarrhea predominant-IBS; IBS-C, constipation predominant-IBS; IBD, inflammatory bowel disease;
TLR9, toll-like receptor 9; CDH1, E-cadherin 1.
3. IBS and the involved immunological response
Several groups have been reporting evidences that suggest 
the development of low grade inflammation in the gut mucosa 
(Table 1), mainly in patients with PI-IBS.
34 Almost 20 years ago, 
Salzmann et al
35 suggested an increased infiltration of mono-
nuclear cells in the lamina propria of patients with IBS. On the 
other hand, the majority of individuals that suffer an acute gastro-
enteritis recover completely after the infectious agent is cleared, 
but a significant group develops FGIDs, such as IBS, functional 
dyspepsia or both.
6,36 It is remarkable that non-gastrointestinal 
infections have also been reported as risk factors for the develop-
ment of IBS.
37
1) Low grade inflammation-immune activation
The concept of low grade inflammation has been coined by 
several groups, and as previously mentioned, it is described as an 
increased infiltration in the colonic mucosa of T lymphocytes, 
mast cells and enteroendocrine cells (Fig. 1).
31,38,39 However, the 
term low immune activation is probably more appropriate. The 
higher number of mast cells present in colonic biopsies, which has 
been reported as a key immunological trait of IBS patients, is an 
important issue.
31,32,40,41 In fact, a higher number of mast cells in 
proximity to the colon sensory nerves
31 have been correlated with 
the severity and frequency of abdominal pain,
40 bloating,
32 and 
probably with rectal hypersensitivity.
38 It is noteworthy that 
Cremon et al
32 reported higher numbers of T and mast cells in 
about 50% of the IBS patients. Their study compared the per-
centage of colonic mucosa infiltrated by immune cells in patients 
with IBS and those with truly inflammatory conditions, such as 
IBD (eg, microscopic colitis, inactive and active ulcerative colitis) 
and healthy controls, finding intermediate infiltration levels in 
IBS patients compared to controls, but lower levels when com-
pared to patients with IBD. The authors concluded that in-
flammation could be a common pathophysiological factor trig-
gering each one of these disorders, where IBS and IBD might 
represent the 2 ends of a wide spectrum of chronic inflammatory 
conditions.Oscar Rodríguez-Fandiño, et al
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Figure 1. Possible immunological responses in the gut mucosa related to developing bowel disorders. In healthy controls there is a tolerogenic 
reaction towards commensal microorganisms. However, it is possible that bacterial populations present in some patients or a genetic predisposition, 
may shift the response towards an immune activation in irritable bowel syndrome (IBS) or to a full-blown inflammatory response in inflammatory 
bowel disease (IBD).
2) Mast cells
Mast cells are distributed along the digestive tract and in all 
layers of the intestinal wall, and might be in a permanent state of 
alert or activation due to the continuous presence of potential an-
tigens within the gastrointestinal lumen.
42 Furthermore, mast cell 
functions are diverse. Traditionally, they have been considered as 
the key effectors cells of allergic reactions. These cells could also 
be of major importance in recruiting and activating eosinophils, B 
and T cells in activated state (presence of CD4+ and CD25+ 
markers).
43,44 On the other hand, mast cells have been involved in 
the communication with intrinsic and extrinsic nerves to modu-
late sensory and motility functioning.
45 It is important to note that 
the resulting reactions from the mediators released by the above 
mentioned cells include responses in the enteric nervous system, 
visceral hiperalgesia and an increased mucosal permeability, as 
well as the generation of symptoms, such as changes in bowel 
habit and abdominal pain.
33,44
3) Enteroendocrine and other immune cells
Other immune cell types have also been observed to be in-
creased in patients with IBS. That is the case for enteroendocrine 
cells, which have been related to PI-IBS.
46 In this subgroup of 
patients, enteroendocrine cells have been reported to be present in 
higher numbers than in any other IBS subgroup.
47 Additionally, 
neutrophils have been reported to be augmented in the gut muco-
sa of patients and in animal models, but unlike the above immune 
cells (mast cells and enteroendocrine cells) these observations 
seem to be scarce
11,48 and possibly this cellular population is not 
an important mediator of the low immune activation present in 
IBS. In addition, the presence of neutrophils would imply a 
full-blown inflammatory process (Fig. 1).
49
4) Lymphocytes
Chadwick et al,
11 reported increased numbers of T cells ex-
pressing CD25+ in the lamina propria of the colon that could be 
related with the low immune activation in the bowel.
50 Recently, it 
has been hypothesized that CD4+ CD25+ T regulatory (Treg) 
cells are reduced in numbers and in their functional capabilities, 
producing an inadequate suppression of intestinal inflammatory 
activity.
51 However, research data from Holmén et al
51 did not 
find a significant difference in the mRNA expression of the 
FoxP3 - a specific marker of Treg cells -, between IBS patients 
and healthy controls, or in the suppressive activity of the periph-
eral CD4+ CD25+ cells from patients and controls. Despite the 
above research, the study was not able to rule out the possibility 
that the colonic Treg cells are dysfunctional in vivo or that alter-
ation of other mucosal immunological cells with suppressive ac-
tivity could be associated with the low grade inflammation that is 
found in the gut of patients with IBS.
51 
Recently, Öhman et al,
39 reported several alterations in pe-
ripheral blood T cells, such as the presence of CD69+ lympho-
cytes (early activation) and the integrin alpha4beta7, receptor 
(intestinal homing) (Fig. 2). The same group
52 also described a 
state of B cell activation, finding increased CD80 and CD86 ex-
pression, at least in a subpopulation of IBS patients. In addition, 
the slight but significant difference in the over expression of IgG 
and alpha4beta7, together with the increased expression of CD80 
and CD86, suggests that IBS patients also have increased B cell 
activation in the extra-intestinal lymph nodes.
52 In order to ex-
plain this cellular infiltrate, Ohman and Simrén
47 suggested 2 
possible explanations: (1) It could be due to an unregulated mild 
inflammation or (2) It can reflect a potent inflammatory sup-
pressive process led by activated T lymphocytes. However, as of 
today, the profile of cytokines released by mast cells, enter-
oendocrine cells, T and B lymphocytes and Treg cells in IBS, as 
well as the level of activation of the infiltrated lymphocytes in the 
gut mucosa of these patients, is unknown.
5) IBS and microscopic colitis
The finding of increased numbers of T cells in the lamina 
propria of the colon in a subgroup of IBS patients,
11 may need to From Cytokines to Toll-Like Receptors in IBS
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Figure 2. Integrative model of irritable bowel syndrome (IBS) pathophysiology. IBS can develop from centrally dominant factors such as stress or 
luminal factors like dysbiosis triggering an altered immune response. Stress alters gastrointestinal motility mediated through the hypothalamic- 
pituitary-adrenal (HPA) axis, and these motility abnormalities can modify the microbiota with the subsequent immune activation in the mucosa and 
stimulation of nerve terminals, generating symptoms of IBS. On the other hand, dysbiosis related to gastrointestinal infections, small intestine 
bacterial overgrowth or antibiotics may increase the epithelial permeability leading to contact between pathogens-associated molecular patterns 
(PAMPs) and toll-like receptors (TLRs) in the deeper layers of the gut with the subsequent host immunity response and IBS generation or symptom 
exacerbation. CRF, corticotrophin-releasing factor.
be differentiated from the presence of microscopic colitis. 
Microscopic colitis is a syndrome of chronic watery diarrhea with 
a chronic inflammatory cell infiltrate in the colonic mucosa, a nor-
mal colonic appearance in the colonoscopy and no laboratory ab-
normalities, therefore, the clinical presentation may be indis-
tinguishable from diarrhea predominant-IBS (IBS-D).
53,54 In 
fact, Limsui et al
55 have reported that 41% to 56% of patients 
with mcroscopic colitis, met symptom criteria for IBS. Also, 
Chey et al
56 found that the overall prevalence of microscopic col-
itis in suspected IBS patients is 1.5% and 2.3% in those older 
than 45 years. On the other hand, classic microscopic colitis en-
compases 2 subgroups, collagenous colitis and lymphocytic 
colitis.
53 The first one has an abnormally thickened subepithelial 
collagen band and the second one, has increased intraepithelial 
lymphocytes (IELs).
53 Therefore, lymphocitic colitis may be sim-
ilar with IBS respect to low grade inflammation, however, in mi-
croscopic colitis  the IELs are increased from 5 per 100 surface 
epithelial cells in normal subjects, to 20 or more per 100 epithelial 
cells.
57 Hence, colonoscopy with multiple biopsies is crucial to 
rule out microscopic colitis
53,54 and to differentiate it from IBS. 
Furthermore, very recent data presented in abstract form have 
confirm that there is no difference between IBS and controls in 
the number of IELs from the cecum, transverse and sigmoid co-
lon, and both groups have less than 10 IELs×100 enterocytes,
58 Oscar Rodríguez-Fandiño, et al
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confirming the last statement.
4. Immune response molecules 
The gastrointestinal tract, as well as other organs lined with 
mucosal tissue, is the first line of defense against luminal antigens 
and environmental pathogens. The epithelial cells in the mucosa 
form a layer that avoids the paracellular transit of substances with 
high molecular weight, such as pathogens or antigens. Also these 
cells produce large amounts of mucus and secrete anti-microbial 
peptides which limit bacterial populations.
59 Under physiological 
conditions this epithelial barrier is not completely impermeable to 
all bacteria, developing a tolerogenic immune response.
60 On the 
other hand, bacteria or other antigens pass through the para-
cellular space, leading to a local and transitory pro-inflammatory 
cytokine production that can slightly inhibit invasion
60,61 by mi-
cro organisms (Fig. 2). This response occurs rapidly and does not 
trigger a measurable systemic pro-inflammatory state.
61 
1) Cytokines
Research on the immunological response in IBS has been led 
by the analysis of differences in cytokines expression. Cytokines 
are intercellular signaling proteins, mainly produced by immune 
cells (mast cells, macrophages, glial cells and lymphocytes in 
proximity with afferent primary non-adrenergic non-cholinergic 
nerves in the gut mucosa). Their main function is to regulate and 
coordinate the immunological response,
62 but they could also play 
an important role in the development of motor dysfunction, vis-
ceral pain and anxiety or depression, mediated by the CNS.
29,62 
Gwee et al
12 opened a research path, when finding higher levels of 
IL-1β mRNA expression in IBS patients both shortly after a gas-
trointestinal infection and three months after the infection was 
cleared. Later, O’Mahony et al
63 reported an abnormal ratio of 
immunoregulatory/proinflammatory IL-10/IL-12 cytokines in 
non-stimulated peripheral blood mononuclear cells from patients 
with IBS, indicating an inflammatory state in these patients. In 
addition, the authors related the normalization of this cytokine ra-
tio and the significant symptomatic relief to the use of a probiotic, 
the Bifidobactium infantis 35624. Recently, Liebregts et al
13 re-
ported a markedly higher basal and lipopolysacharide stimulated 
levels of pro-inflammatory cytokines (IL-1β, TNF-α and IL-6) 
released from peripheral blood mononuclear cells in patients with 
IBS. Moreover, the authors suggested that pro-inflammatory cy-
tokines can partly explain symptom manifestations.
13 More re-
cently, O’Mahony et al
64 evidenced a higher IFN-γ and TNF-α 
production from whole blood stimulated with lipopolysacharide 
in an animal model relevant for IBS (rat maternal separation) 
compared to non-stressed rats. Also, Clarke et al
65 using the same 
rat model, showed correlations between the IL-6 and the poly-
unsaturated fatty acid profile (negative correlations with omega-3 
total levels, and positive correlations with the omega-6/omega-3 
ratio), suggesting a phenotype that is primed for immune acti-
vation. Also, several other pro-inflammatory (IL-2, IL-12, IL- 
17 and IL-18) and anti-inflammatory (IL-4 and IL-13) cytokin-
es have been shown to be present in a lesser extent in IBS.
62 
2) Role of cytokines
The specific roles displayed by cytokines in IBS patients are 
not fully established. Microarray studies have supported the hy-
pothesis of an immune activation, as they have shown a reduced 
expression of immunoregulatory cytokines together with an over 
expression of the pro-inflammatory ones.
66 However, the cyto-
kines are able to start several processes in different cellular types. 
For example, in vitro studies have demonstrated neuronal activa-
tion, probably mediated by glial cells, based on the fact these cells 
have a high density of receptors for cytokines and chemokines.
67 
The above suggests neuronal excitation mediated by intermediate 
cellular populations (glial cells). When stimulated by cytokines, 
the glial and endothelial cells locally release nitric oxide, arach-
idonic acid, prostaglandins, oxygen reactive species and ex-
citatory aminoacids (mainly glutamate), which could modify the 
neuronal activity.
68 Also, glial cells can produce chemokines 
which in turn can induce attraction of immunological cells, am-
plifying the inflammatory signals.
68,69 
3) Chemokines
However, the roles played by chemokines in IBS are not yet 
fully understand, and only a small number of studies have re-
ported changes in these molecules. For example, Dinan et al
29,70 
reported increased levels of the chemokine IL-8/CXCL8. At the 
same time, MacSharry et al
66 reported reduced levels in both the 
expression and secretion levels of chemokines (IL-8/CXCL8; 
CXCL9 and monocyte chemotactic protein-1) in the colonic mu-
cosa of IBS patients. The above findings are controversial and 
warrant the search of additional markers (eg, lactoferrin, calpro-
tectin, reactive C protein and myeloperoxidase) that can become 
biomarkers in IBS and that can explain the underlying biological 
mechanisms as well.
71  
5. Toll-like receptors
The innate immune system is the first line of defense and is 
promptly activated against pathogens or tissue damage, after the 
recognition of several pathogens-associated molecular patterns 
(PAMPs) or danger associated molecular patterns (DAMPs).
72 From Cytokines to Toll-Like Receptors in IBS
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The most studied receptors for PAMPs and DAMPs are the 
TLRs, which have a significantly specific response in the innate 
immunity.
73 Phylogenetic analysis classifies the TLRs in three 
main branches, which seem to correspond with the recognized li-
gands: (1) TLRs 1, 2, 4, 6 and 10 are involved with lipids recog-
nition, (2) TLRs 5 and 11 recognize proteins and (3) TLRs 3, 7, 
8 and 9 are sensitive to nucleic acids.
74 TLRs display differential 
expression levels through the gut mucosal layers, with a spatial 
and cellular specific allocation probably related to their function. 
It is remarkable how changes in the integrity of the epithelial 
barrier or permeability dysfunction lead to contact between 
PAMPs and TLRs in the deeper layers of the gut and the sub-
sequent host immunity response (Fig. 2).
75 However, despite the 
fact that there is not yet a study that has related mucosal perme-
ability with TLRs in IBS patients, research has suggested that 
permeability abnormalities are related to IBS generation and 
symptom exacerbation, especially in the PI-IBS and IBS-D 
subgroups.
10,76,77 I n  f a c t ,  e x  v i v o  a s s a y s  h a v e  s h o w n  a n  a u g -
mented permeability in all IBS subgroups based on bowel habit 
predominance,
78 although the mechanisms involved in these 
changes are unknown. Recent reports have suggested alterations 
in the tight junction proteins, and their physiological processes 
are the possible underlying mechanisms of these changes.
79
Despite the fact that the TLRs are deeply related with some 
gastrointestinal chronic inflammatory disorders such as ulcerative 
colitis or Crohn’s disease,
75,80 available data regarding their par-
ticipation in the pathophysiology of IBS is quite limited. Recent-
ly, Brint et al,
81 reported a 5-fold up-regulation of TLR4 in wom-
en with IBS compared to healthy controls, while reporting a re-
duced expression of TLR7 and TLR8 in the same patients.  
On the other hand, McKernan et al,
82 based on a rat model 
for IBS, reported many differences in the TLRs expression in 
chronically stressed rats compared to controls. The authors used 
2 different models (maternal separation and stress susceptible 
Wistar-Kyoto rats), showing a significantly higher expression of 
the TLR3, 4 and 5 on both, while the Wistar-Kyoto which are 
genetically susceptible to stress, also had a significant over ex-
pression in the TLRs 7, 8 and 9 compared to the Sprague-Dawley 
which are not genetically susceptible to stress. The reasons in-
volved in these differences are not clear; however, alterations in 
the gut microbiota could be related.  
More recently, Villani et al
22 evidenced the complex genetic 
scenario present in the gut mucosa of IBS patients. In this key 
study, the presence of genetic variants involved with TLR9, IL-6 
and intestinal permeability E-cadherin, were found to be in-
dependent risk factors for developing IBS following an episode of 
acute gastroenteritis.
6. Microbiota interactions
The role of TLRs in the pathophysiology of IBS must be 
linked to the extremely taxonomically complex and ecologically 
dynamic community inside the gut, which comprises around 
1,000 different species,
83 the microbiota
84 and the fine immune 
response, developing a tolerogenic reaction towards these com-
mensal microorganisms in addition to the strongly combative re-
sponse against the pathogenic agents.
85 An abnormal or un-
balanced response is currently considered a relevant issue in ex-
plaining the mechanisms underlying IBD. Although the relation-
ship between the gut mucosal response and microbiota has not 
been completely elucidated in IBS, microbiota alterations due to 
the use of systemic antibiotics,
86 small intestine bacterial over-
growth (SIBO)
87-89 or acute gastroenteritis,
90 are extensively con-
sidered risk factors for the development of IBS. In contrast, the 
use of some probiotics has proven to be effective in improving 
symptoms of IBS.
34
Despite the complexity of the gut flora ecosystem, some com-
mensal microorganisms have been significantly related to IBS, 
including increased Clostridium perfringens (or more diverse 
Clostridium spp. in general) or decreased Bifidobacteria.
91-93 
Similarly, Codling et al
94 reported higher gut microbial instability 
and diversity in controls compared to patients. In addition to the 
related immune mechanisms, very recently Tana et al
95 also in-
troduced the concept of the association of organic acids produced 
by bacterial fermentation derived from higher levels of Veillonella 
and Lactobacillus spp. with IBS. In summary, the available data 
has suggested the presence of a dysbiotic microbiota, especially in 
patients with IBS-D, even though the overall structure is similar 
between patients and healthy controls.
96  
Finally, Collins et al
97 have proposed that contrary to what 
occurs in normal subjects following a gastrointestinal infection or 
after the use of antibiotics, where the changes of microbiota are 
temporary and completely restored, in patients with IBS a vicious 
cycle is developed, where intestinal physiological changes, could 
lead to modifications of the bacterial diversity and richness. In ad-
dition, modifications in the microbiota, may trigger changes in 
the motor function and gut sensitivity, and perhaps produce a 
positive feedback sustaining the motility abnormalities and vis-
ceral hypersensitivity (Fig. 2). Oscar Rodríguez-Fandiño, et al
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Conclusion
In recent years there has been an increase in the knowledge of 
the pathophysiological mechanisms related to IBS. However, the 
evidence obtained from other chronic pain syndromes, where bio-
logical, psychological and cultural factors interact in a multi-
factorial fashion similar to what occurs in IBS, suggests that the 
data from research studies must be used with caution.
98 Several 
elements are involved in this complex disorder, including an un-
balanced immune response, dysbiosis or abnormalities in the in-
testinal permeability, all of them interacting to develop IBS. We 
must highlight that the mechanisms underlying the microbiota 
and host interaction warrant further research to elucidate the 
communication processes between the immune and the nervous 
system. We believe that the TLRs and their subsequent cellular 
activation and production of messenger molecules in IBS need to 
be investigated. In addition, the single contribution of each TLR 
and the interaction between 2 or more of these receptors to induce 
cellular activation and the mechanisms by which this event can af-
fect the pathophysiology of IBS, also deserves future research. 
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14. Malinen E, Rinttilä T, Kajander K, et al. Analysis of fecal microbiota 
of irritable bowel syndrome patients and healthy controls with re-
al-time PCR. Am J Gastroenterol 2005;100:373-382.
15. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, et al. The fecal mi-
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